Ashley Grace

speaker

507 appearances 1 recordings 1 series first heard Jul 2026 last heard 23 Jul

Ashley Grace’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

Fully Alive: Unlocking the secrets to your healthier, happier, longer life · Cellular Frequency: Shifting Aging and Human Performance With Ashley Grace · 23 Jul 2026 podcast

So clearly the addition of this igniton energy, which sounds you know very science fiction-y, clearly that that the introduction of that led to an improved outcome.

Now what we're very clear about

is we don't know necessarily why.

We think clearly what happened is it either amplified the ingredients effectiveness or it increased bioavailability for those ingredients, or it did both.

We don't know which one it is, why.

We just know that the the outcome of what we observed.

But the hypothesis is that since we are enhancing the hydrogen molecules with those ingredients, that that's allowing our body to process those ingredients in an e amplified or more by available manner, because our body is 70% water, which is dominated by H2, which is hydrogen.

So seems like a logical hypothesis that by enhancing the hydrogen molecules of these ingredients, that's what's leading to the positive outcomes.

The other product that we have went through the exact same testing protocol, and it's a longevity-focused product.

designed to work on stress and inflammation biomarkers.

And so the ingredients in that one are nicotineamide, ribose, resveratrol, reduced glutathione, berberine, L-methylfolate, PQQ, and cycloastrogenol.

And again, same study design, three prongs, the test results showed

a significant performance in favor of the ignaton-charged formulation in lowering the biomarker interleukin-6 or IL6 by 37%.

The results for C-reactive protein or CRP were lowered by 28%.

And GGT, which is a liver biomarker, was reduced by 13%.

And then

And blood pressure, both s systolic and diastolic blood blood pressure were lowered eight and nine percent.

Again, all of those results being statistically greater than the baseline and greater than the non-charge formulation and placebo.

Really, it's a good idea.

And those were 30 days as well, Zach.

Showing 181–200 of 507 · page 10 of 26